{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:22Z","timestamp":1791357382500,"version":"4.3.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from\n                      <jats:italic>Cannabis sativa<\/jats:italic>\n                      L. that has been purified into 1:1 ratio of CBD and delta-9-tetrahydrocannabinol) in the treatment of psychiatric disorders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and method<\/jats:title>\n                    <jats:p>A systematic review was conducted including case reports, case series, open-label trials, non-randomized and randomized controlled trials (RCTs). The search resulted in 23 relevant studies on CBD and nabiximols in the treatment of a wide range of psychiatric disorders. The quality of evidence was judged by using the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence that ranges from Level 1 to Level 5 based on the quality and study design. These levels of evidence help in grading the recommendations, including Grade A (strong), Grade B (moderate), Grade C (weak), and Grade D (weakest).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CBD and CBD-containing compounds such as nabiximols were helpful in alleviating psychotic symptoms and cognitive impairment in patients with a variety of conditions, and several studies provided evidence of effectiveness in the treatment of cannabis withdrawal and moderate to severe cannabis use disorder with Grade B recommendation. There is Grade B recommendation supporting the use of CBD for the treatment of schizophrenia, social anxiety disorder and autism spectrum disorder (ASD), and attention deficit hyperactivity disorder (ADHD). Grade C recommendation exists for insomnia, anxiety, bipolar disorder, posttraumatic stress disorder, and Tourette syndrome. These recommendations should be considered in the context of limited number of available studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CBD and CBD-containing compounds such as nabiximols were helpful in alleviating symptoms of cannabis-related disorders, schizophrenia, social anxiety disorder, and comorbidities of ASD, and ADHD with moderate recommendation. However, there is weaker evidence for insomnia, anxiety, bipolar disorder, posttraumatic stress disorder, and Tourette syndrome. The evidence for the use of CBD and CBD-containing compounds for psychiatric disorders needs to be explored in future studies, especially large-scale and well-designed RCTs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-019-0012-y","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T08:02:44Z","timestamp":1577952164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["The therapeutic role of Cannabidiol in mental health: a systematic review"],"prefix":"10.1186","volume":"2","author":[{"given":"Rabia","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-7081","authenticated-orcid":false,"given":"Sadiq","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Fida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdur","family":"Raafey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil Kiran","family":"Aedma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","volume":"71","author":"DJ Allsop","year":"2014","unstructured":"Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, Booth J, McGregor IS. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71:281\u201391.","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"12_CR2","first-page":"1521","volume":"9","author":"D Barchel","year":"2018","unstructured":"Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, Koren G, Berkovitch M. Oral Cannabidiol use in children with autism Spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol. 2018;9(9):1521.","journal-title":"Front Pharmacol"},{"issue":"6","key":"12_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schr\u00f6der N, Nardi AE, Mart\u00edn-Santos R, Hallak JE, Zuardi AW, Crippa JA. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219\u201326. https:\/\/doi.org\/10.1038\/npp.2011.6 Epub 2011 Feb 9.","journal-title":"Neuropsychopharmacology."},{"issue":"4","key":"12_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"EM Blessing","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825\u201336.","journal-title":"Neurotherapeutics"},{"issue":"7","key":"12_CR5","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo-controlled trial. Psychopharmacology. 2018;235(7):1923\u201332.","journal-title":"Psychopharmacology"},{"issue":"7","key":"12_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG. Potential adverse drug events and drug\u2013drug interactions with medical and consumer Cannabidiol (CBD) use. J Clin Med. 2019;8(7):989.","journal-title":"J Clin Med"},{"key":"12_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2018.08.021","volume":"161","author":"C Citti","year":"2018","unstructured":"Citti C, Palazzoli F, Licata M, Vilella A, Leo G, Zoli M, Vandelli MA, Forni F, Pacchetti B, Cannazza G. Untargeted rat brain metabolomics after oral administration of a single high dose of cannabidiol. J Pharm Biomed Anal. 2018;161:1\u201311.","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"12_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","volume":"27","author":"RE Cooper","year":"2017","unstructured":"Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit\/hyperactivity disorder: a randomized-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795\u2013808.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"12_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"JA Crippa","year":"2011","unstructured":"Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Sim\u00f5es MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Filho AS. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121\u201330.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"12_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jcpt.12018","volume":"38","author":"JADS Crippa","year":"2013","unstructured":"Crippa JADS, Hallak JEC, Machado-de-Sousa JP, Queiroz RHC, Bergamaschi M, Chagas MHN, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 2013;38(2):162\u20134.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"12_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","volume":"29","author":"A Giuffrida","year":"2004","unstructured":"Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterk\u00f6tter J, Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29(11):2108\u201314.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"12_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","volume":"32","author":"JE Hallak","year":"2010","unstructured":"Hallak JE, Machado-de-Sousa JP, Crippa JA, Sanches RF, Trzesniak C, Chaves C, Bernardo SA, Regalo SC, Zuardi AW. Performance of schizophrenic patients in the Stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Braz J Psychiatry. 2010;32(1):56\u201361.","journal-title":"Braz J Psychiatry"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","volume":"269","author":"E Hoch","year":"2019","unstructured":"Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, Hasan A, Pogarell O. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269:87\u2013105.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"12_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Garth CW, Hoyer C, Klosterk\u00f6tter J, Hellmich M, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(3):e9.","journal-title":"Transl Psychiatry"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","volume":"269","author":"DJ Lowe","year":"2019","unstructured":"Lowe DJ, Sasiadek JD, Coles AS, George TP. Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci. 2019;269:107\u201320.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1017\/S2045796018000239","volume":"27","author":"GM Mandolini","year":"2018","unstructured":"Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018;27:327\u201335.","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"4","key":"12_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s13311-015-0382-6","volume":"12","author":"MW Manseau","year":"2015","unstructured":"Manseau MW, Goff DC. Cannabinoids and schizophrenia: risks and therapeutic potential. Neurotherapeutics. 2015;12(4):816\u201324.","journal-title":"Neurotherapeutics"},{"issue":"65","key":"12_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0024-3205(99)00281-7","volume":"9","author":"BR Martin","year":"1999","unstructured":"Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci. 1999;9(65):573\u201395.","journal-title":"Life Sci"},{"issue":"3","key":"12_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u201331.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"12_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"26","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O'Sullivan SE. A systematic review on the pharmacokinetics of Cannabidiol in humans. Front Pharmacol. 2018;26(9):1365.","journal-title":"Front Pharmacol"},{"key":"12_CR21","unstructured":"OCEBM Levels of Evidence Working Group 2011 The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http:\/\/www.cebm.net\/index.aspx?o=5653. Accessed 19 June, 2019."},{"issue":"12","key":"12_CR22","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.7150\/ijms.27087","volume":"15","author":"E Papaseit","year":"2018","unstructured":"Papaseit E, P\u00e9rez-Ma\u00f1\u00e1 C, P\u00e9rez-Acevedo AP, Hladun O, Torres-Moreno MC, Muga R, Torrens M, Farr\u00e9 M. Cannabinoids: from pot to lab. Int J Med Sci. 2018;15(12):1286\u201395.","journal-title":"Int J Med Sci"},{"key":"12_CR23","doi-asserted-by":"crossref","unstructured":"Peres FF, Lima AC, Hallak JE, Crippa JA, Silva RH, Ab\u00edlio VC. Cannabidiol as a promising strategy to treat and prevent movement disorders? Front Pharmacol. 2018;9(482).","DOI":"10.3389\/fphar.2018.00482"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1038\/sj.ijo.0803272","volume":"1","author":"RG Pertwee","year":"2006","unstructured":"Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;1:S13\u20138.","journal-title":"Int J Obes"},{"issue":"2","key":"12_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/0091217418791455","volume":"54","author":"EM Pichler","year":"2019","unstructured":"Pichler EM, Kawohl W, Seifritz E, Roser P. Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: a case report. Int J Psychiatry Med. 2019;54(2):150\u20136.","journal-title":"Int J Psychiatry Med"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2217\/fnl-2016-0035","volume":"12","author":"I Pokorski","year":"2017","unstructured":"Pokorski I, Clement N, Phung N, Weltman M, Fu SF, Copeland J. Cannabidiol in the management of in-patient cannabis withdrawal: clinical case series. Future Neurol. 2017;12:133\u201340.","journal-title":"Future Neurol"},{"issue":"8","key":"12_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037\u201343.","journal-title":"Neurochem Res"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"2333794X1881541","DOI":"10.1177\/2333794X18815412","volume":"5","author":"Carlos A. Salgado","year":"2018","unstructured":"Salgado CA, Castellanos D (2018) Autism Spectrum disorder and Cannabidiol: have we seen this movie before?. Glob Pediatr Health 5:2333794X18815412.","journal-title":"Global Pediatric Health"},{"issue":"5","key":"12_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ptr.2625","volume":"23","author":"C Scuderi","year":"2009","unstructured":"Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009;23(5):597\u2013602.","journal-title":"Phytother Res"},{"issue":"18","key":"12_CR30","first-page":"041","volume":"23","author":"S Shannon","year":"2019","unstructured":"Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23(18):041.","journal-title":"Perm J"},{"issue":"6","key":"12_CR31","first-page":"31","volume":"14","author":"S Shannon","year":"2015","unstructured":"Shannon S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med (Encinitas). 2015;14(6):31\u20135.","journal-title":"Integr Med (Encinitas)"},{"issue":"4","key":"12_CR32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7812\/TPP\/16-005","volume":"20","author":"S Shannon","year":"2016","unstructured":"Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016;20(4):108\u201311.","journal-title":"Perm J"},{"issue":"1","key":"12_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/can.2017.0043","volume":"3","author":"N Solowij","year":"2018","unstructured":"Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Y\u00fccel M. Therapeutic effects of prolonged Cannabidiol treatment on psychological symptoms and cognitive function in regular Cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res. 2018;3(1):21\u201334.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"6","key":"12_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/1039856216663737","volume":"24","author":"D Trainor","year":"2016","unstructured":"Trainor D, Evans L, Bird R. Severe motor and vocal tics controlled with Sativex\u00ae. Australas Psychiatry. 2016;24(6):541\u20134.","journal-title":"Australas Psychiatry"},{"key":"12_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","volume":"161","author":"JM Trigo","year":"2016","unstructured":"Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 2016a;161:298\u2013306.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"12_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190768","volume":"13","author":"JM Trigo","year":"2018","unstructured":"Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, Staios G, Le Foll B. Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS One. 2018;13(1):e0190768.","journal-title":"PLoS One"},{"issue":"4","key":"12_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/ADM.0000000000000229","volume":"10","author":"JM Trigo","year":"2016","unstructured":"Trigo JM, Soliman A, Staios G, Quilty L, Fischer B, George TP, Rehm J, Selby P, Barnes AJ, Huestis MA, Le Foll B. Sativex associated with behavioral-relapse prevention strategy as treatment for Cannabis dependence: a case series. J Addict Med. 2016b;10(4):274\u20139.","journal-title":"J Addict Med"},{"issue":"1","key":"12_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0269881108096521","volume":"24","author":"A Zuardi","year":"2010","unstructured":"Zuardi A, Crippa J, Dursun S, Morais S, Vilela J, Sanches R, Hallak J. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24(1):135\u20137.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"12_CR39","first-page":"153","volume":"28","author":"AW Zuardi","year":"2006","unstructured":"Zuardi AW. History of cannabis as a medicine: a review. Braz J Med Biol. 2006;28(2):153\u20137.","journal-title":"Braz J Med Biol"},{"issue":"8","key":"12_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V. Cannabidiol for the treatment of psychosis in Parkinson disease. J Psychopharmacol. 2009;23(8):979\u201383.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"12_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0269881106060967","volume":"20","author":"AW Zuardi","year":"2006","unstructured":"Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20(5):683\u20136.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"12_CR42","first-page":"485","volume":"56","author":"AW Zuardi","year":"1995","unstructured":"Zuardi AW, Morais SL, Guimar\u00e3es FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56(10):485\u20136.","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-019-0012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42238-019-0012-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-019-0012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T16:15:38Z","timestamp":1613319338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-019-0012-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1186\/s42238-019-0012-y","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not needed for this review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}